Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped funding

Conditions

ER-positive Breast Cancer
HER2-negative Breast Cancer
Metastatic Cancer

Interventions

DRUG: Onapristone
DRUG: Fulvestrant

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]